THE FUTURE OF DIAGNOSTICS
Accurate, rapid, digital detection of infections in any bodily fluid to indicate in real-time which drugs will be most effective at the point-of-prescription.
Today the US spends $20B+ on infection detection. The market for efficient bacteria resistance detection has enormous potential. Avails Medical is pioneering the current diagnostics market with a groundbreaking technology that targets this global health threat.
Avails Medicals’ cost-effective platform will transform the diagnostics market by enabling for the first time diagnostic-guided therapy at the point-of-care, reducing time-to-treatment from days to minutes.